Ind-Swift Laboratories (NSE:INDSWFTLAB) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)


NSE:INDSWFTLAB Ind-Swift Laboratories Ltd NSE:INDSWFTLAB
55 GF Score
Price ₹214.16
GF Value ₹36.95
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ind-Swift Laboratories LT-Debt-to-Total-Asset?

Ind-Swift Laboratories NSE:INDSWFTLAB +3.85% 55 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates NSE:INDSWFTLAB with a GF Score™ of 55/100 and a GF Value™ of ₹36.95 (Significantly Overvalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ind-Swift Laboratories's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

Ind-Swift Laboratories's long-term debt to total assets ratio increased from Dec. 2024 (0.00) to Mar. 2026 (0.01). It may suggest that Ind-Swift Laboratories is progressively becoming more dependent on debt to grow their business.

Ind-Swift Laboratories  (NSE:INDSWFTLAB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ind-Swift Laboratories LT-Debt-to-Total-Asset Related Terms

Ind-Swift Laboratories LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Ind-Swift Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ind-Swift Laboratories LT-Debt-to-Total-Asset Chart

Ind-Swift Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.41 0.14 0.02 0.01

Ind-Swift Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.02 0.01 0.00 0.01
NSE:INDSWFTLAB
55GF Score
Ind-Swift Laboratories Ltd NSE:INDSWFTLAB
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ind-Swift Laboratories LT-Debt-to-Total-Asset Calculation

Ind-Swift Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=123.029/16733.498
=0.01

Ind-Swift Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=123.029/16733.498
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Ind-Swift Laboratories (NSE:INDSWFTLAB) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ind-Swift Laboratories and its competitors.
Is Ind-Swift Laboratories' LT-Debt-to-Total-Asset too high?
Ind-Swift Laboratories' current LT-Debt-to-Total-Asset is 0.01. Overall, Ind-Swift Laboratories has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ind-Swift Laboratories' LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Ind-Swift Laboratories' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ind-Swift Laboratories and its competitors. Ind-Swift Laboratories's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ind-Swift Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ind-Swift Laboratories (NSE:INDSWFTLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹36.95, compared to a current price of ₹214.16 — trading 479.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. Ind-Swift Laboratories' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Ind-Swift Laboratories (NSE:INDSWFTLAB), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued. The current stock price of ₹214.16 is trading 479.6% above its estimated GF Value™ of ₹36.95. GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.

Key valuation signals for NSE:INDSWFTLAB:

  • LT-Debt-to-Total-Asset: 0.01
  • GF Value™: ₹36.95 vs. price of ₹214.16 (479.6% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the NSE:INDSWFTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ind-Swift Laboratories Business Description

Other Exchanges 532305:India
Address SCO 850, NAC, Shivalik Enclave, Manimajra, Chandigarh, PB, IND, 160101
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
55GF Score

Get the complete analysis for NSE:INDSWFTLAB

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹214.16
Price
₹36.95
GF Value